IMTX

AI Memo

Immatics

As of 2026-10-02/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

low

Horizon

—

Key catalyst

IMA203CD8 Phase 1 data at ESMO • 2026-10-23

Base target: $9 / p=45% prob

Biggest risk

SUPRAME remains unproven in a randomized trial, and slower-than-modeled endpoint events could affect timing. Q2 R&D expense rose to $71.1 million from $51.4 million a year earlier as clinical programs advanced; financing needs or disappointing clinical data could materially impair equity value. Company Q2 release

Invalidation

Break below $5 or thesis failure.

What would change my mind?

October program-specific data could broaden confidence in the PRAME franchise, while a positive randomized SUPRAME result could support the planned 2027 BLA. The company reported $448.2 million of cash and other financial assets at June 30 and projected cash reach into 2028. Company Q2 release

Research note

Recommendation

—

Confidence

low

As of

2026-10-02

Base target

p=45%

Bull target

$14

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Anzu-cel SUPRAME pivotal readout
October program-specific data could broaden confidence in the PRAME franchise, while a positive randomized SUPRAME result could support the planned 2027 BLA.
The company reported $448.2 million of cash and other financial assets at June 30 and projected cash reach into 2028.

BearKey bullets

October IMA203CD8 and IMA402 updates are early-stage data and may not show durable benefit or an acceptable safety profile.
Rising trial and commercialization-preparation spending could shorten the projected runway or require additional financing.
Company Q2 release

WatchKey bullets

IMA203CD8 Phase 1 data at ESMO

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=45%)

Target spread vs base: +59% / -47%

Scenario probabilities

Bull Target: $14 (p=25%)Base Target: $9 (p=45%)Bear Target: $5 (p=30%)

Commentary

Zero-valued sentiment fields indicate unavailable measurements, not neutral readings. No reliable post-release price-reaction series or analyst-revision history was supplied. The packet records an August 26 open-market purchase by director Perceptive Advisors, an ownership signal rather than evidence of trial success. [#SEC-FORM4-2026-08-27] SEC Form 4 The packet's automated earnings snapshot differs from the company's Q2 figures, so the company release governs financial claims.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Anzu-cel SUPRAME pivotal readout

Scenarios

Bull Target (Scenario probability)

$14 / p=25% prob

Base Target (Scenario probability)

$9 / p=45% prob

Bear Target (Scenario probability)

$5 / p=30% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-23
IMA203CD8 Phase 1 data at ESMO
The October 23 presentation is scheduled to update response durability across PRAME-positive tumors, including gynecologic cancers. Durability and tolerability matter more than an early response-rate headline. [#PR-ESMO-2026-07-17] Company announcement
Prob 45.00% • Move 10.00% • Priced-in 30.00%
EVENT2026-10-24
IMA402 Phase 1b data at ESMO
Immatics has scheduled October 24 data at the recommended Phase 2 dose range. Evidence of durable activity and manageable safety could strengthen this separate bispecific program; early-stage results would not establish approval prospects. [#PR-ESMO-2026-07-17] Company announcement
Prob 40.00% • Move 9.00% • Priced-in 25.00%
EVENT2026-12-31
SUPRAME enrollment milestone
Immatics expects the required Phase 3 randomizations by year-end 2026. Progress would support the planned pivotal-readout timetable, but slower-than-modeled progression-free-survival events remain a timing risk. [#PR-EARNINGS-2026-08-18] Company Q2 release
Prob 70.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Anzu-cel SUPRAME pivotal readout
2027-06-30
The company expects final-analysis topline progression-free-survival data in H1 2027 and plans a BLA submission later in 2027. The randomized result, not Phase 1b activity, is the principal binary valuation test. [#PR-EARNINGS-2026-08-18] Company Q2 release
Prob 45% • Move 35% • Priced-in 35%

Risks

October IMA203CD8 and IMA402 updates are early-stage data and may not show durable benefit or an acceptable safety profile.
Rising trial and commercialization-preparation spending could shorten the projected runway or require additional financing. Company Q2 release
SUPRAME efficacy or safety could disappoint at the randomized final analysis; Phase 1b response data do not resolve that risk.
Slower-than-modeled progression-free-survival events could delay the planned H1 2027 readout. Company Q2 release

Peers

Symbol	Summary
IOVA	Advanced-melanoma cell-therapy comparator, though Iovance's TIL approach differs from Immatics' PRAME-directed TCR-T therapy. Iovance filing
IMCR	TCR-based oncology comparator; different products and indications limit direct valuation transfer. Iovance filing discussing the competitive set

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

IOVA

Advanced-melanoma cell-therapy comparator, though Iovance's TIL approach differs from Immatics' PRAME-directed TCR-T therapy. Iovance filing

IMCR

TCR-based oncology comparator; different products and indications limit direct valuation transfer. Iovance filing discussing the competitive set